Alunbrig (brigatinib)
- Region
- 🇪🇺 EU
- Active substance
- brigatinib
- Company
- Takeda Pharma A/S
- Status
- Authorised
- Therapeutic area
- Carcinoma, Non-Small-Cell Lung
- CHMP opinion
- Wed 19 Sep 2018
- EU approval
- Thu 22 Nov 2018
- Application
- EMEA/H/C/004248
- ATC
- L01XE43
- Official record
- www.ema.europa.eu
Indication
Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)?positive advanced non?small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase ALKpositive advanced NSCLC previously treated with crizotinib.
Regulatory milestones
No milestones recorded in the last year.
Follow Alunbrig
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.